DE69939707D1 - Varianten der humanen glycosylphosphatidylinositol-spezifischen phospholipase d und ihre verwendungen - Google Patents
Varianten der humanen glycosylphosphatidylinositol-spezifischen phospholipase d und ihre verwendungenInfo
- Publication number
- DE69939707D1 DE69939707D1 DE69939707T DE69939707T DE69939707D1 DE 69939707 D1 DE69939707 D1 DE 69939707D1 DE 69939707 T DE69939707 T DE 69939707T DE 69939707 T DE69939707 T DE 69939707T DE 69939707 D1 DE69939707 D1 DE 69939707D1
- Authority
- DE
- Germany
- Prior art keywords
- pld
- gpi
- specific phospholipase
- variants
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101000730493 Homo sapiens Phosphatidylinositol-glycan-specific phospholipase D Proteins 0.000 title 1
- 102100032538 Phosphatidylinositol-glycan-specific phospholipase D Human genes 0.000 abstract 4
- 108010045724 glycoprotein phospholipase D Proteins 0.000 abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000005976 liver dysfunction Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9828715.4A GB9828715D0 (en) | 1998-12-24 | 1998-12-24 | Glycosylphosphatidylinositol specific phospholipase d protiens and uses thereof |
| GBGB9828712.1A GB9828712D0 (en) | 1998-12-24 | 1998-12-24 | Glycosylphosphatidylinositol specific phospholipase d proteins and usues thereof |
| GBGB9828713.9A GB9828713D0 (en) | 1998-12-24 | 1998-12-24 | Glycosylphosphatidylinositol specific phospholipase d protiens and uses therof |
| PCT/GB1999/004399 WO2000039285A2 (en) | 1998-12-24 | 1999-12-23 | Human glycosylphosphatidylinositol specific phospholipase d variants and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69939707D1 true DE69939707D1 (de) | 2008-11-20 |
Family
ID=27269604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69939707T Expired - Fee Related DE69939707D1 (de) | 1998-12-24 | 1999-12-23 | Varianten der humanen glycosylphosphatidylinositol-spezifischen phospholipase d und ihre verwendungen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1141334B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002533119A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE410516T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU774986B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2355468A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69939707D1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000039285A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0015625D0 (en) * | 2000-06-26 | 2000-08-16 | Univ London | Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| GB0015986D0 (en) * | 2000-06-29 | 2000-08-23 | Univ London | Glycosylphosphatidylinositol specific phospholipase d proteins or the treatment or diagnosis of atherosclerosis |
| AU2004251690A1 (en) * | 2003-06-04 | 2005-01-06 | Duke University | Compositions and methods for modulating S-nitrosoglutathione reductase |
| CA2906540C (en) * | 2013-03-15 | 2021-01-12 | Amgen Inc. | Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477739A3 (en) * | 1990-09-27 | 1992-12-09 | F. Hoffmann-La Roche Ag | Glycosyl-phosphatidylinositol-specific phospholipase d |
| CA2321113A1 (en) * | 1998-03-18 | 1999-09-23 | Thomas William Rademacher | Anti-inositolphosphoglycan monoclonal antibodies |
-
1999
- 1999-12-23 JP JP2000591177A patent/JP2002533119A/ja active Pending
- 1999-12-23 EP EP99963641A patent/EP1141334B1/en not_active Expired - Lifetime
- 1999-12-23 AT AT99963641T patent/ATE410516T1/de not_active IP Right Cessation
- 1999-12-23 AU AU19883/00A patent/AU774986B2/en not_active Ceased
- 1999-12-23 CA CA002355468A patent/CA2355468A1/en not_active Abandoned
- 1999-12-23 DE DE69939707T patent/DE69939707D1/de not_active Expired - Fee Related
- 1999-12-23 WO PCT/GB1999/004399 patent/WO2000039285A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002533119A (ja) | 2002-10-08 |
| EP1141334B1 (en) | 2008-10-08 |
| ATE410516T1 (de) | 2008-10-15 |
| WO2000039285A2 (en) | 2000-07-06 |
| AU1988300A (en) | 2000-07-31 |
| CA2355468A1 (en) | 2000-07-06 |
| WO2000039285A3 (en) | 2000-11-16 |
| EP1141334A2 (en) | 2001-10-10 |
| AU774986B2 (en) | 2004-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT93910A (pt) | Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula | |
| DE60128916D1 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| DE69738581D1 (de) | Menschliche dnase i hyperaktive varianten | |
| EP2330127A3 (en) | Kallikrein-inhibiting Kunitz Domain proteins and nucleic acids encoding the same | |
| WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| EP2322201A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| WO2004000997A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
| WO2002050277A3 (en) | Protein and nucleic acids encoding same | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| EP1978362A3 (en) | Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity | |
| ATE209684T1 (de) | Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung | |
| ATE549353T1 (de) | Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen | |
| EP1248847B8 (en) | Irak-4: compositions and methods of use | |
| WO2004042083A3 (en) | Nucleic acid ligands and uses therefor | |
| ATE88500T1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
| ATE277171T1 (de) | Ikk-alpha proteine, nukleinsäuren und verfahren | |
| ATE410516T1 (de) | Varianten der humanen glycosylphosphatidylinositol-spezifischen phospholipase d und ihre verwendungen | |
| ATE395602T1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
| WO2000065028A3 (en) | TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR | |
| WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
| WO2003022998A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
| DE69712182D1 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
| BRPI0308978A8 (pt) | fragmentos de peptídeos sintéticos ativos | |
| BG101846A (bg) | Варианти на човешка дезоксирибонуклеаза i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |